Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia Journal of Hematology & Oncology, 06/12/2012

Chen H et al. – The results indicate that relapse rate can be reduced and diseasefree survival (DFS) may be improved in Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph + ALL) patients with imatinib maintenance therapy after HCT. BCR–ABL monitoring by quantitative reverse–transcription polymerase chain reaction (qRT–PCR) can guide maintenance therapy with imatinib including initiation time and treatment duration after allogeneic hematopoietic stem cell transplantation (allo–HCT)

Read this article on Journal of Hematology & Oncology

Print Article | Back to Articles

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Medical Student Jobs
@MDLinx Career Center
View the full listing of physician jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?